AstraZeneca received another orphan drug designation for Fasenra (benralizumab) for treatment of eosinophilic oesophagitis.

The biologic product is currently approved as an add-on maintenance treatment in severe eosinophilic asthma.

The FDA granted Fasenra orphan drug designation in November 2018 to treat eosinophilic granulomatosis with polyangiitis (EGPA), and in February 2019 to treat hypereosinophilic syndrome (HES).